| Dr Jasmin Kilayko Cole, MD | |
|
6230 Rolling Rd Ste J, Springfield, VA 22152-2326 | |
| (571) 665-6460 | |
| (571) 665-6461 |
| Full Name | Dr Jasmin Kilayko Cole |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 28 Years |
| Location | 6230 Rolling Rd Ste J, Springfield, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720061476 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD067375L (Pennsylvania) | Secondary |
| 207Q00000X | Family Medicine | 0101243642 (Virginia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of The Mid-atlantic States,inc | 3779495858 | 1673 |
News Archive
Eliza Corporation, the pioneer and recognized leader in Health Engagement Management, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a Complex Acoustic Resonance Speech Analysis System.
Approximately 20 percent of homicides of children 2 to 14 years of age in the United States may be related to intimate partner violence, a fact that is currently underreported by the National Violent Death Reporting System, according to a new study from the Harvard T.H. Chan School of Public Health published in the American Journal of Preventive Medicine.
Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC.
Four of five patients participating in a trial of an experimental protocol designed to induce immune tolerance to HLA-mismatched kidney transplants have been able to discontinue immunosuppressive drugs.
'Microbial Pathogenomics' contains a unique collection of reviews demonstrating how genomics has revolutionized our understanding of virulence, host-adaptation strategies and the evolution of bacterial pathogens. Current technologies - computational tools and functional approaches to genome analysis - are carefully documented and clearly illustrated.
› Verified 4 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861552721 PECOS PAC ID: 3779495858 Enrollment ID: O20031105000744 |
News Archive
Eliza Corporation, the pioneer and recognized leader in Health Engagement Management, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a Complex Acoustic Resonance Speech Analysis System.
Approximately 20 percent of homicides of children 2 to 14 years of age in the United States may be related to intimate partner violence, a fact that is currently underreported by the National Violent Death Reporting System, according to a new study from the Harvard T.H. Chan School of Public Health published in the American Journal of Preventive Medicine.
Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC.
Four of five patients participating in a trial of an experimental protocol designed to induce immune tolerance to HLA-mismatched kidney transplants have been able to discontinue immunosuppressive drugs.
'Microbial Pathogenomics' contains a unique collection of reviews demonstrating how genomics has revolutionized our understanding of virulence, host-adaptation strategies and the evolution of bacterial pathogens. Current technologies - computational tools and functional approaches to genome analysis - are carefully documented and clearly illustrated.
› Verified 4 days ago
| Entity Name | Inova Health Care Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952320061 PECOS PAC ID: 2466351093 Enrollment ID: O20080806000696 |
News Archive
Eliza Corporation, the pioneer and recognized leader in Health Engagement Management, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a Complex Acoustic Resonance Speech Analysis System.
Approximately 20 percent of homicides of children 2 to 14 years of age in the United States may be related to intimate partner violence, a fact that is currently underreported by the National Violent Death Reporting System, according to a new study from the Harvard T.H. Chan School of Public Health published in the American Journal of Preventive Medicine.
Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC.
Four of five patients participating in a trial of an experimental protocol designed to induce immune tolerance to HLA-mismatched kidney transplants have been able to discontinue immunosuppressive drugs.
'Microbial Pathogenomics' contains a unique collection of reviews demonstrating how genomics has revolutionized our understanding of virulence, host-adaptation strategies and the evolution of bacterial pathogens. Current technologies - computational tools and functional approaches to genome analysis - are carefully documented and clearly illustrated.
› Verified 4 days ago
| Entity Name | Inova Ucc Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508592114 PECOS PAC ID: 7012385040 Enrollment ID: O20221123001904 |
News Archive
Eliza Corporation, the pioneer and recognized leader in Health Engagement Management, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a Complex Acoustic Resonance Speech Analysis System.
Approximately 20 percent of homicides of children 2 to 14 years of age in the United States may be related to intimate partner violence, a fact that is currently underreported by the National Violent Death Reporting System, according to a new study from the Harvard T.H. Chan School of Public Health published in the American Journal of Preventive Medicine.
Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC.
Four of five patients participating in a trial of an experimental protocol designed to induce immune tolerance to HLA-mismatched kidney transplants have been able to discontinue immunosuppressive drugs.
'Microbial Pathogenomics' contains a unique collection of reviews demonstrating how genomics has revolutionized our understanding of virulence, host-adaptation strategies and the evolution of bacterial pathogens. Current technologies - computational tools and functional approaches to genome analysis - are carefully documented and clearly illustrated.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jasmin Kilayko Cole, MD 6230 Rolling Rd Ste J, Springfield, VA 22152-2326 Ph: (571) 665-6460 | Dr Jasmin Kilayko Cole, MD 6230 Rolling Rd Ste J, Springfield, VA 22152-2326 Ph: (571) 665-6460 |
News Archive
Eliza Corporation, the pioneer and recognized leader in Health Engagement Management, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a Complex Acoustic Resonance Speech Analysis System.
Approximately 20 percent of homicides of children 2 to 14 years of age in the United States may be related to intimate partner violence, a fact that is currently underreported by the National Violent Death Reporting System, according to a new study from the Harvard T.H. Chan School of Public Health published in the American Journal of Preventive Medicine.
Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC.
Four of five patients participating in a trial of an experimental protocol designed to induce immune tolerance to HLA-mismatched kidney transplants have been able to discontinue immunosuppressive drugs.
'Microbial Pathogenomics' contains a unique collection of reviews demonstrating how genomics has revolutionized our understanding of virulence, host-adaptation strategies and the evolution of bacterial pathogens. Current technologies - computational tools and functional approaches to genome analysis - are carefully documented and clearly illustrated.
› Verified 4 days ago
Meredith Lynn Porter, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6230 Rolling Rd Ste J, Springfield, VA 22152 Phone: 571-665-6460 Fax: 571-665-6461 | |
Dr. Sonya Nadine Bethel, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7440 Spring Village Dr, Springfield, VA 22150 Phone: 703-923-4644 Fax: 703-923-4625 | |
Dr. Sally R Hayes, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 6230 Rolling Rd Ste Iandj, Springfield, VA 22152 Phone: 571-665-6460 Fax: 571-565-6561 | |
Jeffrey K Nekoba, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7489 Huntsman Blvd, Springfield, VA 22153 Phone: 571-642-1460 Fax: 703-440-1203 | |
Dr. Farah Saeed, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6501 Loisdale Ct, Kaiser Permanente Springfield Medical Center, Springfield, VA 22150 Phone: 703-922-1000 | |
Dr. Priya Jagannathan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6501 Loisdale Ct, Springfield, VA 22150 Phone: 703-944-7662 | |
Mrs. Rebecca Mensah, FNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 8020 Pohick Rd, Springfield, VA 22153 Phone: 571-484-0443 |